MTOR and subependymal giant cell astrocytoma: In addition to the primary endpoints evaluating safety and kidney angiomyolipoma response, we investigated the utility of mTOR inhibitor treatment for many common clinical features of TSC by collecting secondary endpoint data on liver angiomyolipomas, subependymal giant cell astrocytomas (SEGAs), tubers, subependymal nodules (SENs), seizures, skin lesions (facial angiofibromas, hypomelanotic macules, shagreen patches, forehead plaques), renal cysts, kidney function, and lung function in those individuals with LAM.